Rare diseases
Investigational molecules
Locations
Recruiting trials first
1 clinical trial in this condition
Study on the Safety and Effectiveness of Crofelemer for Children with Microvillus Inclusion Disease (MVID)
ItalyIn short
Microvillous inclusion disease is a rare genetic condition affecting newborns, causing life-threatening diarrhea and severe malnutrition from the earliest days of life. Managing this condition requires specialized medical care, long-term nutritional support, and in some cases, advanced surgical interventions to help children survive and grow.
When a baby is diagnosed with microvillous inclusion disease, the primary aim of treatment is to keep the child alive by preventing dangerous dehydration and providing essential nutrients that their body cannot absorb from food. Unlike many childhood illnesses that resolve with time or medication, this condition requires lifelong management because the intestinal cells simply cannot perform their normal job of absorbing nutrients and fluids. Treatment focuses heavily on maintaining proper nutrition, preventing complications, and supporting normal growth and development as much as possible.
The treatment approach depends on several factors, including how early the symptoms appeared, how severe the diarrhea is, and whether the child develops complications over time. Some children show symptoms within hours of birth, while others may not experience problems until they are a few months old. The later the onset, the milder the symptoms tend to be, which can influence treatment decisions. Medical teams also consider the child's overall health, the family's ability to manage complex home care, and access to specialized centers equipped to handle rare intestinal diseases.
Currently, medical societies recognize that there are no standard drug treatments that can cure or reverse microvillous inclusion disease. Instead, approved treatment guidelines focus on supportive care, which means providing what the body needs externally since the intestine cannot do its job internally. At the same time, researchers around the world are actively investigating new therapies through clinical trials. These studies test innovative approaches that might one day offer children with this condition a better quality of life or even restore some intestinal function.
The cornerstone of standard treatment for microvillous inclusion disease is parenteral nutrition, often abbreviated as PN or TPN (total parenteral nutrition). This technique involves delivering all the nutrients a child needs directly into the bloodstream through a special type of intravenous line called a central venous catheter. This catheter is essentially a permanent IV that goes directly into a large vein near the heart, allowing nutrients to bypass the digestive system entirely and enter the blood where they can nourish the body.
Parenteral nutrition solutions are carefully designed to include everything a growing child needs: proteins to build tissues, fats for energy and brain development, carbohydrates for fuel, vitamins to support metabolism, minerals for bone growth, and electrolytes to maintain proper fluid balance. Each child's formula is individualized based on their age, weight, growth rate, and any complications they may be experiencing. Medical teams regularly monitor blood tests to adjust the nutritional formula and ensure the child is receiving optimal support.
The duration of parenteral nutrition therapy is lifelong for most children with microvillous inclusion disease. Unlike some intestinal conditions where the bowel can eventually recover, the genetic defect causing this disease means the intestinal cells will never function normally. Children typically receive parenteral nutrition every day, often connecting to the IV solution in the evening and running it overnight while they sleep. This approach allows them to be disconnected during the day for school and normal activities, though the schedule varies based on individual needs.
In addition to nutritional support, doctors focus on managing hydration and preventing dehydration. When children with this condition eat or drink, their diarrhea often worsens dramatically. Infants can lose enormous amounts of fluid—sometimes liters per day—which can lead to severe dehydration within hours. Standard oral rehydration solutions, which work well for typical diarrhea, are ineffective in microvillous inclusion disease because the intestinal cells cannot absorb the fluid. Therefore, intravenous fluids are essential, especially during acute episodes of illness or when diarrhea increases.
The medical team also monitors for and treats complications related to long-term parenteral nutrition. The most concerning is liver disease, specifically cholestasis, a condition where bile flow from the liver becomes reduced or blocked. This can progress to cirrhosis, or irreversible liver scarring, which is life-threatening. Doctors monitor liver function through regular blood tests and may adjust the parenteral nutrition formula, particularly the fat content, to reduce liver stress. Infections are another significant risk because the central line provides a direct pathway for bacteria to enter the bloodstream. Families learn strict sterile techniques for handling the catheter, and any signs of infection—fever, chills, or redness around the catheter site—require immediate medical attention.
Some children may tolerate small amounts of oral feeding, particularly those with later-onset, milder forms of the disease. While they cannot meet their nutritional needs by mouth, allowing some oral intake helps maintain normal eating behaviors and provides psychological benefits. However, feeding typically increases stool output significantly, so the amount and type of food must be carefully managed. Most families work with specialized dietitians who understand intestinal failure to find the right balance.
Side effects of long-term parenteral nutrition are numerous and can significantly impact quality of life. Beyond liver disease and infections, children may experience problems with bone health, developing osteoporosis (thinning of the bones) due to altered mineral metabolism. Kidney stones and gallstones occur more frequently. Growth may be slower than normal despite adequate nutrition. Developmental delays can occur, sometimes related to repeated hospitalizations and medical procedures rather than the disease itself. Blood clots can form in the large veins where catheters are placed, limiting options for future catheter placement. Managing these complications requires a multidisciplinary team including gastroenterologists, nutritionists, nurses, social workers, and sometimes other specialists.
When parenteral nutrition causes severe complications or is no longer feasible due to vein damage or liver failure, intestinal transplantation becomes the next treatment option. This is a complex surgical procedure where a donor small intestine replaces the child's non-functioning intestine. Sometimes the liver must also be transplanted if it has been severely damaged by long-term parenteral nutrition, resulting in a combined intestine-liver transplant.
Intestinal transplantation is considered only at specialized transplant centers with expertise in this rare procedure. The surgery itself carries significant risks, and recovery is long and challenging. After transplant, children must take lifelong immunosuppressive medications to prevent their body from rejecting the new organ. These medications suppress the immune system, making children more vulnerable to infections. Despite these challenges, successful transplantation can free a child from dependence on parenteral nutrition, allowing them to eat normally and significantly improving their quality of life.
The decision about when to proceed with transplantation is complex and individualized. Some medical centers advocate for early transplantation before severe complications develop, arguing this provides the best long-term outcomes. Others prefer to delay as long as possible, recognizing that advances in parenteral nutrition have made it increasingly safe over time. Families must weigh the risks of continued parenteral nutrition against the risks and demands of transplantation. Medical teams at centers experienced in both intestinal failure and transplantation can help families make informed decisions.
Research into microvillous inclusion disease has accelerated significantly in recent years, driven by identification of the genetic causes and development of laboratory models that mimic the disease. Scientists have created organoids—tiny, lab-grown structures made from patients' own intestinal stem cells that function like mini intestines. These organoids show the same problems seen in patients' actual intestines, providing a powerful tool for understanding the disease and testing potential treatments without risking harm to patients.
One of the most promising experimental approaches involves using a drug called crofelemer to reduce fluid loss from diarrhea. Researchers studying patient-derived organoids discovered that the severe diarrhea in microvillous inclusion disease occurs because intestinal cells lose their ability to absorb sodium and water, while their ability to secrete chloride and water remains normal. The net result is massive fluid loss. Crofelemer works by blocking chloride channels, thereby reducing the amount of chloride and water that gets secreted into the intestine. While this does not fix the underlying sodium absorption problem, it could significantly reduce fluid loss and improve quality of life.
Crofelemer is already approved for treating diarrhea in adults with HIV or those undergoing chemotherapy, so its safety profile is well understood. Researchers recently obtained permission from the U.S. Food and Drug Administration to test crofelemer in children with microvillous inclusion disease in a clinical trial. This represents a Phase II trial, where the primary goal is to determine whether the drug effectively reduces symptoms in this specific patient population. Boston Children's Hospital is expected to be the first site where this trial opens, with additional sites worldwide joining later given the rarity of the condition. If successful, this could become the first medication specifically targeting symptoms of microvillous inclusion disease.
Another experimental approach aims to correct the root cause of the disease by restoring the missing or malformed microvilli—the tiny finger-like projections on intestinal cells that absorb nutrients. In healthy intestines, microvilli dramatically increase the surface area available for absorption. In microvillous inclusion disease, these structures are either absent, poorly formed, or trapped inside the cell rather than on its surface where they belong. Researchers testing drugs called gamma-secretase inhibitors in organoid models found that these compounds could partially rescue microvillus structure and restore some sodium absorption function.
The mechanism behind this improvement involves complex cellular signaling pathways that control how and where microvilli form. Gamma-secretase inhibitors interfere with a pathway that appears to be overactive in microvillous inclusion disease, and blocking this pathway allows cells to form more normal microvilli. However, gamma-secretase inhibitors affect many processes throughout the body and can cause significant side effects, so they are not ready for clinical testing. Instead, researchers are now working to identify more specific targets within this pathway that could provide the benefits without the harmful effects. This represents early-stage research, roughly equivalent to Phase I work, focused on understanding mechanisms and developing safer potential therapies.
Scientists have also conducted comprehensive genetic analyses of cells from patients with microvillous inclusion disease, comparing them to healthy intestinal cells. These studies have identified numerous genes that are turned on or off abnormally in the disease, providing a roadmap of potential therapeutic targets. Some of these targets might be addressable with existing drugs originally developed for other conditions, which could speed the path to clinical trials. Other targets might require development of entirely new medications. This work is ongoing and represents the foundation for future treatment approaches.
Research has also revealed that several different genes can cause microvillous inclusion disease, including MYO5B, STX3, STXBP2, and UNC45A. While these genes are different, they all affect the same basic process: moving proteins and other materials to the correct location on the intestinal cell surface. Understanding the specific genetic cause in each patient may eventually allow for personalized treatment approaches. For example, therapies targeting problems caused by MYO5B mutations might differ from those targeting STX3 mutations.
Some clinical trials focus on improving outcomes of intestinal transplantation or developing better methods of providing long-term parenteral nutrition. These may not target the disease itself but can significantly improve the lives of children living with microvillous inclusion disease. Families interested in clinical trials should discuss options with their child's medical team and consider connecting with specialized centers conducting research on this condition.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
